Keyphrases
Calcitonin Gene-related Peptide
82%
Migraine
77%
Migraine Attack
63%
Migraine without Aura (MWoA)
30%
Migraine Pathophysiology
27%
Predictive Biomarker
27%
Migraine Prevention
27%
Erenumab
27%
Blood-brain Barrier
27%
Premonitory Symptoms
27%
Central Nervous System
18%
Monthly Migraine Days
15%
Intravenous Infusion
11%
Trigeminal Ganglion
9%
Neurological Diseases
9%
Sensory Afferents
9%
Vasodilation
9%
All Ages
9%
Molecular Pathogenesis
9%
Site of Action
9%
Barrier Dysfunction
9%
Lessons Learned
9%
Nociceptive Transmission
9%
Sphenopalatine Ganglion
9%
Headache
7%
Moderate to Severe
6%
Disease Burden
6%
Predictive Value
6%
Migraine Days
6%
Severe Intensity
6%
Trial Registration
5%
Cutaneous Allodynia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Calcitonin Gene Related Peptide
82%
Erethism
30%
Migraine Aura
27%
Biological Marker
27%
Erenumab
27%
Symptom
27%
Headache
16%
Migraine with Aura
9%
Allodynia
7%
Medicine and Dentistry
Migraine
72%
Calcitonin Gene Related Peptide
55%
Biological Marker
27%
Migraine Aura
27%
Erenumab
27%
Symptom
27%
Hypersensitivity
27%
Infusion
18%
Headache
14%
Auras
10%
Migraine with Aura
6%
